Peer Review History

Original SubmissionJune 23, 2020
Decision Letter - Hasnain Seyed Ehtesham, Editor

PONE-D-20-17556

The epidemiology of extrapulmonary tuberculosis in China: A large-scale multi-center observational study

PLOS ONE

Dear Dr. Tang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 03 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Hasnain Seyed Ehtesham

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for indicating in the Methods section that your ethics board provided approval and that they waived the need for informed patient consent because the study was restrospective and used anonymized data. Please additionally add this information to the Ethics Statement.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

4. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The article is good as it presents a huge data collected from 21 hospitals in the country. In the limitations the authors have mentioned that they could not compare the demographic details as income, housing, smoking etc. They also mentioned that they could not procure much data about paediatric tuberculosis.

They have only mentioned number of tuberculosis cases and concurrent pulmonary tuberculosis cases.

However, the following points need to be mentioned:

1. BCG vaccination policy of China and the vaccination status of the patients.

2. Immune status of the patients with underlying illnesses.

3. The number of cases with previous TB infection.

4. Rate of cure and mortality.

The authors have presented huge amount of data but they haven't correlated the data with the above mentioned points and have not related to any demographic details, that is required to be done.

Reviewer #2: Comments:

As per title and objective, the article written by Kang et al. provides full illustration of epidemiology of EPTB in China. This observational study represented about 202,998 EPTB inpatients with collaboration of 21 hospitals from 15 provinces in China.

However, following suggestive comments will also construct this article stronger and beneficial for the readers:

Abstract:

• Word limits excided as per Journal guidelines. Should be modified while considering word limit.

• Abbreviations of PTB are missing.

Introduction:

• It is advised to add few points with recent references regarding diagnostic modalities and difficulties in diagnosing EP specimens as it is missing form introduction section.

Method:

• Author must specify about bronchial tuberculosis (14.96%), because this may consider under PTB.

Results:

• Risk of EPTB is related to the degree of exposure to the pathogen and host immune factors like HIV, diabetes, malignancy etc. It’s my opinion that if author have the related data then this could make article more encouraging to readers.

Discussion:

• Line no. 282: Mycobacterium tuberculosis , write in italic.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

PONE-D-20-17556

The epidemiology of extrapulmonary tuberculosis in China: A large-scale multi-center observational study

PLOS ONE

Dear Academic Editor Hasnain Seyed Ehtesham,

On behalf of my co-authors, we thank you very much for giving us an opportunity to revise our manuscript. We have tried our best to revise our manuscript according to the comments. At the same time, the revised version has been uploaded.

We are pleased to answer the questions raised by the academic editor and reviewers and the manuscript has also been revised according to the comments.

Journal Requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Answer: Thank you very much. Our manuscript meets PLOS ONE's style requirements.

2. Thank you for indicating in the Methods section that your ethics board provided approval and that they waived the need for informed patient consent because the study was retrospective and used anonymized data. Please additionally add this information to the Ethics Statement.

Answer: The information has been added to the ethics statement.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Answer: I have an ORCID iD and that it is validated in Editorial Manager.

4. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

Answer: The ethics statement has been added to the Methods of the manuscript.

Reviewer's Responses to Questions

Reviewer #1: The article is good as it presents a huge data collected from 21 hospitals in the country. In the limitations the authors have mentioned that they could not compare the demographic details as income, housing, smoking etc. They also mentioned that they could not procure much data about paediatric tuberculosis.

They have only mentioned number of tuberculosis cases and concurrent pulmonary tuberculosis cases.

However, the following points need to be mentioned:

1. BCG vaccination policy of China and the vaccination status of the patients.

Answer: BCG vaccination policy of China: newborns are given BCG vaccination. BCG vaccination status of our group of patients was not investigated.

2. Immune status of the patients with underlying illnesses.

Answer: Sorry, the immune status of this group of patients was not detected.

3. The number of cases with previous TB infection.

Answer: Regrettably, previous TB infection in these patients was not included in our investigation.

4. Rate of cure and mortality.

Answer: Rate of cure and mortality of this group of patients were not investigated in this survey.

The authors have presented huge amount of data but they haven't correlated the data with the above mentioned points and have not related to any demographic details, that is required to be done.

Reviewer #2: Comments:

However, following suggestive comments will also construct this article stronger and beneficial for the readers:

Abstract:

• Word limits excided as per Journal guidelines. Should be modified while considering word limit.

Answer: According to the guidance of the magazine, the number of words in the abstract meets the requirements.

• Abbreviations of PTB are missing.

Answer: It has been modified as required.

Introduction:

• It is advised to add few points with recent references regarding diagnostic modalities and difficulties in diagnosing EP specimens as it is missing form introduction section.

Answer: We have added the EPTB diagnostic difficulties in the introduction.

Method:

• Author must specify about bronchial tuberculosis (14.96%), because this may consider under PTB.

Answer: Tracheobronchial tuberculosis (TBTB) is a type of tuberculosis that occurs in the mucosa, submucosa, smooth muscle, cartilage, and membrane of the trachea and bronchial. Previously bronchial tuberculosis was classified as extrapulmonary tuberculosis in China.

Results:

• Risk of EPTB is related to the degree of exposure to the pathogen and host immune factors like HIV, diabetes, malignancy etc. It’s my opinion that if author have the related data then this could make article more encouraging to readers.

Answer: Thank you very much for your suggestion. But, we don't have data on the degree of exposure to the pathogen and host immune factors in our survey.

Discussion:

• Line no. 282: Mycobacterium tuberculosis, write in italic.

Answer: In 282 lines of the manuscript, Mycobacterium Tuberculosis has been italicized.

Thank you very much for your attention and consideration. I am looking forward to hearing from you.

Yours Sincerely,

Shenjie Tang

Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China

Email: tangsj1106@hotmail.com, tangsj1106@vip.sina.com

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Hasnain Seyed Ehtesham, Editor

The epidemiology of extrapulmonary tuberculosis in China: A large-scale multi-center observational study

PONE-D-20-17556R1

Dear Dr. Tang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hasnain Seyed Ehtesham

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I have gone through this revised manuscript and also the Author response to the comments of the Reviewers. Required information has been added to the Ethics Section and also ethics statements have been added to the Methods of the manuscript by the Authors. Missed Abbreviations of PTB is modified as required and Authors have also added the diagnostic modalities and difficulties in diagnosing EP specimens which was missing from the introduction section.The authors have satisfactorily addressed all the comments made by the reviewers and added all required information, and have revised the manuscript accordingly. I recommend this manuscript for publication.

Reviewers' comments:

Formally Accepted
Acceptance Letter - Hasnain Seyed Ehtesham, Editor

PONE-D-20-17556R1

The epidemiology of extrapulmonary tuberculosis in China: A large-scale multi-center observational study

Dear Dr. Tang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Hasnain Seyed Ehtesham

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .